{"id":"gbt009","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Limited public information is available regarding GBT009's specific mechanism of action. As a Phase 2 asset from Garnet BioTherapeutics, the drug is still in early-stage clinical evaluation, and detailed mechanistic data have not been widely disclosed in the public domain.","oneSentence":"GBT009 is an investigational therapeutic targeting an undisclosed molecular pathway in early clinical development.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T04:00:56.327Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT01053897","phase":"PHASE2","title":"Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery","status":"COMPLETED","sponsor":"Garnet BioTherapeutics, Inc.","startDate":"2010-01","conditions":"Scar Formation","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"GBT009","genericName":"GBT009","companyName":"Garnet BioTherapeutics, Inc.","companyId":"garnet-biotherapeutics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}